China's E-Cigarette Export Data to Canada in February 2023

Industry Insight by 2FIRSTS
Apr.03.2024
China's E-Cigarette Export Data to Canada in February 2023
Chinese e-cigarette exports to Canada in February 2023 declined by 41.80% from previous month, but rose by 25.01% year-on-year.

According to the latest trade data updated by the General Administration of Customs of the People's Republic of China, 2FIRSTS has compiled the e-cigarette export data from China to Canada in February 2023. The specifics are as follows:

China's E-Cigarette Export Data to Canada in February 2023
Image source: 2FIRSTS (Mincy diagram)

 

The export volume was approximately 15.06 million US dollars, a decrease of 41.80% compared to the previous month but an increase of 25.01% compared to the same period last year.

China's E-Cigarette Export Data to Canada in February 2023
Image source: 2FIRSTS (Created by Mincy)

 

The export volume is approximately 303 tons, a decrease of 43.24% from the previous period, and an increase of 47.00% compared to the same period last year.

China's E-Cigarette Export Data to Canada in February 2023
Image source: 2FIRSTS (Mapped by Mincy)

 

The export unit price is 49.55 US dollars per kilogram, with a month-on-month increase of 2.53% and a year-on-year decrease of 14.96%; the average price of "e-cigarettes and similar personal electronic vaporization devices" is 3.11 US dollars per unit.

China's E-Cigarette Export Data to Canada in February 2023
Image source: 2FIRSTS (Mincy illustration)

 

Among them, e-cigarettes and similar personal electronic vaporization devices account for 25.76% of the export category, while products containing nicotine that do not include tobacco or reconstituted tobacco and are not intended for combustion account for 74.24%.

China's E-Cigarette Export Data to Canada in February 2023
Image source: 2FIRSTS (created by Mincy)

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Smoore's Subsidiary CCELL Faces Antitrust Lawsuit in the U.S., Accused of Price Manipulation and Market Monopoly
Smoore's Subsidiary CCELL Faces Antitrust Lawsuit in the U.S., Accused of Price Manipulation and Market Monopoly
A U.S. federal court in Arizona has recently accepted a class-action lawsuit against Chinese e-cigarette manufacturer Smoore and its U.S. distributor. The suit accuses them of monopolizing the U.S. cannabis vape market through price manipulation and market division, resulting in higher costs for consumers. This marks the second such case filed this year.
Jul.03 by 2FIRSTS.ai
FDA & CBP Seize Nearly 2 Million Illegal E-Cigarette Products
FDA & CBP Seize Nearly 2 Million Illegal E-Cigarette Products
The FDA and CBP seized nearly 2 million unauthorized e-cigarettes in Chicago this February, worth $33.8 million. Most came from China, involving brands like Snoopy Smoke and Raz. The FDA sent warning letters to 24 importers for using false labels to evade inspection.
May.23 by 2FIRSTS.ai
China’s STMA Holds E-cigarette Regulatory Press Conference, Discloses Policy Enforcement and Industry Development Guidelines
China’s STMA Holds E-cigarette Regulatory Press Conference, Discloses Policy Enforcement and Industry Development Guidelines
May.28 by 2FIRSTS.ai
Singapore Launches Anti-Vaping Campaign Using Satirical Designs to Warn Teens of Risks
Singapore Launches Anti-Vaping Campaign Using Satirical Designs to Warn Teens of Risks
Singapore’s Health Promotion Board and TBWA\Singapore launched the “Don’t Toy With Your Life” anti-vaping campaign, using satirical toy-like designs to expose vaping risks. The campaign spans digital media and public transport, targeting youth vaping and will run until August 2025 on popular social and streaming platforms.
Jul.11 by 2FIRSTS.ai
Samsung Wins US E-Cigarette Battery Explosion Lawsuit; Judge Rules It Didn’t Enter Consumer Market
Samsung Wins US E-Cigarette Battery Explosion Lawsuit; Judge Rules It Didn’t Enter Consumer Market
Samsung SDI escaped liability in a U.S. lawsuit over a vape battery explosion after an appeals court ruled it had no direct ties to the consumer vape market and took steps to prevent unauthorized use of its batteries.
Jul.16 by 2FIRSTS.ai
U.S. FDA Unveils AI Tool Elsa for Clinical Review, Internal Writing, and Data Processing
U.S. FDA Unveils AI Tool Elsa for Clinical Review, Internal Writing, and Data Processing
The U.S. Food and Drug Administration has officially launched Elsa, a generative AI tool designed to speed up clinical reviews, internal writing, and data processing tasks. After successful pilots across multiple departments, Elsa is now being rolled out agency-wide.
Jun.04 by 2FIRSTS.ai